Payment overview · 2025
General Payments
$519.21
27 reported records · 12 companies
Healthcare provider profile · identity verified
Thomas J Ferrari, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SWAINSBORO, GA · NPI 1346249109
Verified facts
What the public records show
CMS Open Payments records show Thomas J Ferrari, MD received $519.21 in general payments during 2025 across 27 reported records.
ABBVIE INC. accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $175.77 | 33.9% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.10 | 14.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.75 | 12.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.85 | 7.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.69 | 7.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.57 | 6.5% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.19 | 3.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.39 | 3.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.97 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.25 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.45 | 2.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.23 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $474.21 | 26 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $100.11 | 7 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $74.10 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.30 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.30 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 81 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 39 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 161 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 162 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
161 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
162 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 470 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 88 |
| Omeprazole | Omeprazole | 336 | 70 |
| Gabapentin | Gabapentin | 295 | 72 |
| Famotidine | Famotidine | 284 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 71 |
| Losartan Potassium | Losartan Potassium | 263 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 51 |
| Tramadol Hcl | Tramadol Hcl | 242 | 54 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 230 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 214 | 66 |
| Furosemide | Furosemide | 200 | 58 |
| Metformin Hcl | Metformin Hcl | 190 | 48 |
| Lisinopril | Lisinopril | 178 | 41 |
| Valsartan | Valsartan | 171 | 32 |
| Potassium Chloride | Potassium Chloride | 170 | 42 |
| Trazodone Hcl | Trazodone Hcl | 170 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 162 | 22 |
| Ozempic | Semaglutide | 162 | 27 |
| Carvedilol | Carvedilol | 161 | 41 |
| Mounjaro | Tirzepatide | 161 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 38 |
| Pregabalin | Pregabalin | 141 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 135 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 133 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 126 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 31 |
| Clonazepam | Clonazepam | 121 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 33 |
| Cefdinir | Cefdinir | 119 | 86 |
| Buspirone Hcl | Buspirone Hcl | 116 | 28 |
| Montelukast Sodium | Montelukast Sodium | 115 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 33 |
| Alprazolam | Alprazolam | 104 | 20 |
| Lorazepam | Lorazepam | 104 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 27 |
| Ondansetron Odt | Ondansetron | 104 | 36 |
| Sertraline Hcl | Sertraline Hcl | 100 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 18 |
| Meloxicam | Meloxicam | 91 | 24 |
| Sucralfate | Sucralfate | 90 | 20 |
| Ezetimibe | Ezetimibe | 89 | 18 |
| Eliquis | Apixaban | 85 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 85 | 15 |
| Celecoxib | Celecoxib | 83 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 34 |
| Farxiga | Dapagliflozin Propanediol | 81 | 18 |
| Allopurinol | Allopurinol | 78 | 18 |
| Levetiracetam | Levetiracetam | 77 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 76 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 18 |
| Promethazine Hcl | Promethazine Hcl | 76 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 18 |
| Methylprednisolone | Methylprednisolone | 72 | 50 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 12 |
| Ibuprofen | Ibuprofen | 71 | 22 |
| Azithromycin | Azithromycin | 69 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 22 |
| Baclofen | Baclofen | 67 | 13 |
| Metformin Hcl Er | Metformin Hcl | 65 | 17 |
| Jardiance | Empagliflozin | 63 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 15 |
| Rybelsus | Semaglutide | 61 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 42 |
| Alendronate Sodium | Alendronate Sodium | 59 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 13 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Vascepa | Icosapent Ethyl | 56 | 12 |
| Topiramate | Topiramate | 54 | 13 |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 53 | 12 |
| Prednisone | Prednisone | 53 | 19 |
| Meclizine Hcl | Meclizine Hcl | 52 | 17 |
| Simvastatin | Simvastatin | 52 | suppressed |
| Mupirocin | Mupirocin | 51 | 17 |
| Colchicine | Colchicine | 50 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | 11 |
| Mirtazapine | Mirtazapine | 45 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 43 | suppressed |
| Glimepiride | Glimepiride | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 14 |
| Fluconazole | Fluconazole | 41 | 18 |
| Glipizide | Glipizide | 41 | suppressed |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 26 |
| Linzess | Linaclotide | 39 | 13 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 13 |
| Eszopiclone | Eszopiclone | 38 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 13 |
| Mometasone Furoate | Mometasone Furoate | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 12 |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Atenolol | Atenolol | 29 | 11 |
| Finasteride | Finasteride | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 28 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Mitigare | Colchicine | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 16 |
| Emgality Pen | Galcanezumab-Gnlm | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Etodolac | Etodolac | 20 | suppressed |
| Nystatin | Nystatin | 20 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Ramelteon | Ramelteon | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Roflumilast | Roflumilast | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ssd | Silver Sulfadiazine | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Glucagen | Glucagon | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $519.21 · 27 records | ABBVIE INC. | AJOVY, CAPLYTA, CREON, ENTRESTO, FANAPT, FARXIGA, GVOKE HYPOPEN, IBSRELA, LEQVIO, LINZESS, MOUNJARO, Ozempic, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, VRAYLAR | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error